Unicycive stockholders approve Nasdaq 20% issuance and share increase at annual meeting

Unicycive Therapeutics, Inc.

All four director nominees elected: Dr. Shalabh Gupta, Dr. Sandeep Laumas, Dr. Gaurav Aggarwal, Dr. Saraswati Kenkare-Mitra.
Appointment of Grassi & Co. CPAs as independent auditor for FY2024 ratified with 35,666,926 votes for.
Nasdaq 20% Issuance Proposal approved with 26,794,427 votes for, 262,272 against.
Authorized Share Increase Proposal approved with 34,150,333 votes for, 1,735,688 against.
Second amendment and restatement of 2021 Omnibus Equity Incentive Plan approved with 26,540,959 votes for.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.